Authors
Hiba Narvel, Daisuke Nishizaki, Shumei Kato, Razelle Kurzrock
Published in
ImmunoTargets and therapy. Volume 15. Pages 585744. Epub Sep 22, 2026.
Abstract
STAT6, located on chromosome 12, encodes a transcription factor whose SH2 domain is central to its activation. While classically a Th2 mediator, aberrant STAT6 activation is observed in diverse malignancies. This review focuses on the molecular and functional landscape of STAT6, primarily in cancer and tumor immunology, while also surveying its emerging roles in allergy, infection, and autoimmunity to illustrate context-dependent signaling and identify areas for future investigation. In tumors, STAT6 fosters immunosuppression by polarizing macrophages toward M2 phenotypes and upregulates checkpoint ligands, while promoting oncogenic phenotypes (survival, angiogenesis, metastasis) through crosstalk with STAT3, NF-κB, and others. STAT6 can be activated both canonically (IL-4/IL-13 via JAKs) and noncanonically (eg, STING signaling). Somatic hotspot mutations (notably D419) enhance DNA binding and nuclear retention, and germline polymorphisms to gain-of-function alleles span a continuum of allergic phenotypes. In infection, STAT6 is essential for helminth clearance but may antagonize protective Th1 responses against viruses and bacteria. In autoimmunity, its role is context-dependent: pathogenic in some settings, regulatory in others. STAT6 emerges as a context-specific "switch node" in immunity and cancer. Its multifaceted contributions highlight the need for further research to determine whether therapeutic targeting-and if so, which biomarker-guided, context-dependent strategies-might be feasible in selected disease settings.
PMID:
42801147
Bibliographic data and abstract were imported from PubMed on 27 Sep 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 12
- Comments 0